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Abstract
Background: Quality control of drugs in formulations is still a major challenge in developing countries. For the
quality control of artesunate and amodiaquine tablets in fixed-dose combination, only liquid chromatographic
methods have been proposed in the literature. There are no capillary electrophoretic methods reported for the
determination of these active substances, although this technique presents several advantages over liquid
chromatography (long lifetime, low price of the capillary, low volumes of electrolyte consumption) in addition to
simplicity. In this paper, a reliable capillary electrophoresis method has been developed and validated for the quality
control of these drugs in commercial fixed-dose combination tablets.
Methods: Artesunate and amodiaquine hydrochloride in bilayer tablets were determined by micellar electrokinetic
capillary chromatography (MEKC). Analytes were extracted from tablets by sonication with a solvent mixture
phosphate buffer pH 7.0-acetonitrile containing benzoic acid as internal standard. Separation was carried out on
Beckman capillary electrophoresis system equipped with fused silica capillary, 30 cm long (20 cm to
detector) × 50 μm internal diameter, using a 25 mM borate buffer pH 9.2 containing 30 mM sodium dodecyl sulfate
as background electrolyte, a 500 V cm−1 electric field and a detection wavelength of 214 nm.
Results: Artesunate, amodiaquine and benzoic acid were separated in 6 min. The method was found to be reliable
with respect to specificity,linearity of the calibration line (r2> 0.995), recovery from synthetic tablets (in the range
98–102%), repeatability (RSD 2–3%, n = 7 analytical procedures). Application to four batches of commercial
formulations with different dosages gave content in good agreement with the declared content.
Conclusion: The MEKC method proposed is reliable for the determination of artesunate and amodiaquine
hydrochloride in fixed-dose combination tablets. The method is well-suited for drug quality control and detection
of counterfeit or substandard medicines.
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Background
Malaria is the most important parasitic disease in the
world which afflicts more than 800 million people.
World Health Organization (WHO) recommends that
artemisinin-based combination therapy (ACT) be used to
counter the threat of Plasmodium falciparum resistance to
artemisinin monotherapies and improve treatment out-
come. Artesunate (AS) plus amodiaquine (AQ) (Figure 1)
is one of the three WHO-recommended forms of ACT
in Africa. Fixed-dose combination (FDC) formulations
are strongly preferred and recommended over blistered
co-packaged or loose tablets combinations to promote
adherence to treatment [1]. FDC for artesunate (AS)
and amodiaquine (AQ) was first registered in 2007
under the brand name ASAQW (Winthrop) for public
market and CoarsucamW (Sanofi) for private market. It is
formulated as bilayer tablets to limit the physical contact
between the active substances and avoid the degradation of
AS which is accelerated in the presence of AQ [2]. Simul-
taneous determination of the two active substances appears
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rather difficult for several reasons such as the absence of
chromophore for AS, the content difference between AS
and AQ (weight ratio AS/AQ 1/2.7 in the formulations),
the complexity of the formulation and the rapid degradation of
AS in solution. Only two high performance liquid chromato-
graphic (HPLC) methods using reverse mode separation have
been reported for AS and AQ determination in FDC tablets
[3,4]. In the method reported by Phadke et al. [3], both com-
pounds are assayed in a single run at two different wavelengths
(210 nm for AS, 300 nm for AQ) using a diode array detector.
The run time was 9 min. In the paper of Gandhi et al. [4], in-
ternal standardization with artemether is used to determine the
two compounds at a unique wavelength (220 nm) using two
test solutions. AS is determined on a mixed concentrated test
solution of tablet (500 mg L-1 AS; 1.5 gL-1 AQ hydrochloride
(AQH)) and AQH is determined on a dilution 1/10 of this test
solution. The run time is about 16 min.
No capillary electrophoresis (CE) method has been
reported concerning the determination of AS and AQ in
pharmaceutical formulations. CE has been used for the
separation of AS from its hydrolysis products [5], from
artelinic acid, a potential anti-malarial drug [6] and for
AS determination in caco-2 cells [7]. AQ has been used
in CE as a model compound to test the efficiency of a
coating agent to prevent adsorption of basic substances
on the capillary wall [8]. Since CE presents distinct
advantages over HPLC in terms of reduced operating
costs and simplicity, the possibility of using CE for the
quality control of AS and AQ in fixed-dose combined
formulations has been investigated in this paper.
Methods
Chemicals
All chemicals and solvents were of analytical grade.
Deionized water distilled from a quartz apparatus was
used throughout. AS and AQH were from Maphar
(Casablanca, Morocco). Benzoic acid (internal standard)
was from Merck (Darmstadt, Germany). Sodium dihydro-
gen phosphate was from Prolabo (Fontenay-sous-Bois,
France), sodium dodecyl sulfate (SDS) was from Fluka (Neu
Ulm, Germany). HPLC grade acetonitrile and sodium
hydroxide were from Carlo Erba (Val de Reuil, France),
hydrochloric acid was from Sigma-Aldrich (Steinheim,
Germany). CoarsucamW (Sanofi-Aventis, Morocco) and
ASAQ DenkW (Denk Pharma, Germany) commercial
tablet formulations were purchased in Côte d’Ivoire.
Solutions
The background electrolyte solution was a 25 mM sodium
borate buffer (pH 9.2) solution containing 30 mM SDS.
The internal standard solution (ISS) was a 50 mg L-1 of
benzoic acid (BA) solution in 10 mM phosphate pH 7 –
acetonitrile (60: 40, v/v) solvent mixture.
A concentrated standard solution (2 g L-1 AS and
7 gL-1 AQH) was prepared by sonication of about 20 mg
AS and 70 mg AQH (accurately weighed) in 10 mL of ISS
(= standard solution solution AS) for AS determination.
This solution was diluted (1/100, v/v) in the ISS (= standard
solution AQ) for AQH determination.
Five tablets were weighed accurately and crushed with
a pestle in a porcelain mortar and thoroughly homoge-
nized. A quantity of tablet powder equivalent to about
20 mg of AS and 70 mg of AQH was accurately weighed
in a 10 mL volumetric flask. After addition of about
7 mL of ISS, the flask was subjected to ultrasonication for
10 min with intermittent shaking, then ISS was added to
the mark. The suspension was centrifuged at 5,000 rpm
for 5 min. and the supernatant (= test solution AS) corre-
sponding to a theoretical concentration of 2 g L−1 AS (and
7 g L-1 AQH) was used for AS determination. This solu-
tion diluted (1/100, v/v) in the ISS for AQH determination
(= test solution AQ) had a 0.07 gL-1 theoretical AQH con-
centration). Standard and test solutions were stable for at
least 24 h at ambient temperature.
Figure 1 Chemical structure of amodiaquine hydrochloride (AQH) and artesunate (AS).
Amin et al. Malaria Journal 2012, 11:149 Page 2 of 7
http://www.malariajournal.com/content/11/1/149
Apparatus and operating conditions
A Beckman P/ACE MDQ (Fullerton, CA) instrument
equipped with a photodiode array detector was used.
Separation was carried out on a fused-silica capillary,
30 cm long (20 cm to the detector), 50 μm internal
diameter (TSP, Composite Metal Services, Hallow,
Worcs, UK), housed in a cartridge with a 200 μm×800
μm detection window. Prior to its first use, the capillary
was preconditioned by washing at 20 psi for 20 min with
a 0.1 M sodium hydroxide solution, and then flushed
with water for 5 min. Every working day a preconditioning
was carried out with 1 M hydrochloride acid followed by
1 M sodium hydroxide, water, and electrolyte buffer at
20 psi for 5 min.
The different stages of the proposed method for AS
and AQ determination are given in Table 1. Standard
and test solutions were placed in bracketting sequence
and duplicate injections were used in each case. Average
corrected peak areas (peak areas divided by their respective
migration times) of analyte/IS were used for calculations.
Results and discussion
To achieve the separation in the shortest time possible,
all experiments were carried out on a short capillary
(30 cm long, 20 cm effective length) with an internal
diameter of 50 μm for an efficient dissipation of heat
produced by Joule effect.
Preliminary studies in capillary zone electrophoresis
First of all, the possibility of using capillary zone electro-
phoresis (CZE) was investigated since the pKa values of
AS (pKa 4.3 (−)) and AQH (pKas 7.1 (+) and 8.1 (+))
show that they can be separated as anion (AS) and cation
(AQ). Background electrolyte solutions in the pH range
7–8 were investigated since at these pH values, AS and
AQ are under anionic and cationic forms respectively,
and there is a high electro-osmotic flow (EOF) for a fast
separation. Using 100 mM phosphate pH 7 and applying
a 10 kV separation voltage, satisfactory separation was
obtained with a standard solution (2.0 g L-1 AS, 0.07 g L-1),
AQ being eluted first as cation (migration time 2.73 min)
and AS as anion at 8.23 min. after the EOF (3.93 min.).
The high concentration of AS (2.0 g L-1) was needed to
have the required sensitivity for AS determination. Test
solutions from tablets contain 2.0 g L-1AS and 7 g L-1
AQH. At this high concentration, AQ disturbed strongly
the baseline for an accurate determination of AS, pre-
venting CZE to be used for AS determination in FDCs.
Further investigations were carried out in Micellar Elec-
trokinetic Capillary Chromatography (MEKC).
Investigations in micellar electrokinetic capillary
chromatography
The different steps of optimization in MEKC are described
below.
Optimization of the surfactant concentration
Sodium dodecyl sulfate (SDS) was selected as micellar
additive to the background electrolyte as it is the most
used anionic surfactant in MEKC and has a low UV ab-
sorbance. A 25 mM sodium borate buffer (natural pH
9.2) was chosen for its high buffer capacity (pKa 9.2) and
its low UV absorbance. At this pH, a high EOF is pro-
vided which speeds up the separation.
Figure 2 shows the influence of SDS concentration (0–
100 mM) on the migration times (MTs) of AS and AQ. At
pH 9.2, AS which has a full negative charge, partitions be-
tween the micelles and the background electrolyte both
through hydrophobic and electrostatic interactions. Because
it is repelled from the micelles, it is eluted first. AQ, which
Table 1 Operating conditions
Operations
1. Capillary rinse 1 M HCl; 2 min; 20 psi
2. Capillary rinse 1 M NaOH; 1 min; 20 psi
3. Capillary rinse Electrolyte solution; 1 min; 20 psi
4. Sample introduction
(anodic side)
Analyte; 3 secondes; 0.3 psi (3.5 nL)
5. Wait Water; 0 seconde
6. Separation 6 min; 10 kV (500 V.cm-1);
0.17 min ramp voltage; 25°C
(i = 50 μA)
7. Detection UV; 214 nm; spectral bandwith
10 nm; acquisition rate 4 Hz;
filter normal
8. Autozero 1 min
Figure 2 Influence of SDS concentration on MTs of AS, AQ, IS
and X (AQ impurity). Operating conditions: 25 mM sodium
tetraborate buffer pH 9.2 with SDS 0 – 100 mM; Capillary, 50 μm I.
D. × 30 cm; 15 kV; 25°C °; λ= 214 nm; inj 3,5 nL.
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is uncharged (eluted in the EOF at 0% SDS concentration),
partitions through hydrophobic interactions and is eluted
late. Selectivity was adjusted by varying the SDS concen-
tration. Increasing SDS concentration has little influence
on EOF velocity (a slight decrease is observed due to com-
pression of the double layer), but dramatically influences
the solute mobilities. As the number of micelles is
increased, the concentration of solute in the micelles
increases resulting in a lower mobility and change in se-
lectivity. Resolution was satisfactory at 5, 10, 30, 75 and
100 mM SDS concentration. The best peak shape and
peak efficiency was obtained at a 30 mM SDS concentra-
tion which was selected for further experiments as the best
compromise in terms of resolution of AS from an AQ im-
purity, peak shape, analysis time and reasonable current
(50 μA). No further optimization was carried out as func-
tion of voltage and borate concentration buffer.
Selection of a sample solvent
It appeared very difficult to find a suitable solvent to ex-
tract quantitatively both AQH and AS from tablets.
Water in which AQH is very soluble could not be used as
AS is not soluble in water at the concentration needed for
its determination (2 gL-1). Methanol, and methanol–water
mixture (1: 1; v/v) which could be potential extraction sol-
vents [9] led frequent current breakdowns due to bubble
formation during the separation. The next approach was to
use a 10 mM phosphate buffer pH 3- acetonitrile mixture
(60: 40, v/v) which has been successfully used for AS and
AQH extraction from CoarsucamW tablets analysed in
HPLC (Afssaps, personal communication). No current
breakdown occurred and injections were repeatable. The
stability of AS in this solvent was assessed.
Electropherograms presented in Figure 3 show that the
degradation of a standard solution of AS and AQ in this
solvent mixture gives rise after 7 day storage at ambient
temperature, to a compound eluted at a MT of about
4.5 min., which is assumed to be the hydrolysis product of
AS, dihydroartemisinin (neutral compound) [5,10-12].The
stability study of AS in the same solvent mixture carried
out over a 24 h period showed that AS in test and standard
solutions is stable only 4–5 h at ambient temperature. Since
hydrolysis is favoured in acidic medium, the pH of the buf-
fer was changed from 3.0 to 7.0 to improve the stability.
Hence, the sample solvent used in the proposed method is
a solution of internal standard in a 10 mM phosphate buffer
pH 7.0- acetonitrile mixture (60: 40, v/v) which provides
quantitative extraction of both compounds. These solutions
are stable at least 24 h at ambient temperature.
Optimization of the injected volume and sample
concentration
It is well known that injection of samples previously dis-
solved in an organic solvent affects peak efficiency and
shape in MEKC, especially if the injected volume is
increased as it causes the micelles near the sample zone to
collapse [13]. Since acetonitrile (40%, v/v) was needed to
solubilize the analytes from the tablets, the injection vol-
ume was reduced to about 3.5 nL (0.6% of the capillary vol-
ume) in order to maintain satisfactory peak efficiency and
peak shape. Injection of larger volumes or more concen-
trated solutions (> 1 gL-1 AQH) resulted in peak splitting.
Selection of an internal standard
The use of an IS is needed for quantitative analysis in CE
to take into account small variations of the injected
volumes due to the injection system. In addition, if it is
added in the extraction solvent (test solution) or dissol-
ution solvent (standard solution) it takes also into ac-
count possible variations due to solvent evaporation.
Among potential IS candidates, procaine (pKa 9), pheno-
barbital (pKa 7.4), and benzoic acid (pKa 4.3) were
tested. Benzoic acid was found to be suitable as it is
eluted between AS and AQ, is separated from AQ im-
purity (fig 3), gives a peak of acceptable efficiency and
yields repeatable extractions of AS and AQ from tablets.
Selection of detection wavelength
Due to the lack of chromophore in AS, detection at a
low wavelength was needed for AS determination. A
214 nm wavelength gave the best signal-to-noise ratio
for AS. This allows the use of a UV detector with filter.
Figure 3 Stability of a standard solution. AS 2 g L-1, AQH
70 mg L-1, and IS 70 mg L-1 in acetonitrile – 10 mM phosphate
pH 3 (40:60, v:v) stored at room temperature. Operating
conditions: background electrolyte, borate – SDS (25 mM sodium
tetraborate buffer pH 9.2 – 30 mM SDS); capillary, 50 μm I.D. × 30 cm
(20 cm); inj 3.5 nL; 15 kV; 25 C; detection, λ= 214 nm.
Dihydroartemisinin (DHA), a degradation product of AS was
observed.
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Capillary rinse between injections
Various rinse solutions (sodium hydroxide 0.1 M and
1 M; hydrochloric acid 0.1 M and 1 M) and rinsing time
(1–3 min) were tested to avoid capillary fouling. Best
performances were obtained using rinse cycles indicated
in Table 1.
Typical electropherograms of standard and test solu-
tions analysed under the final selected conditions of
Table 1 are shown in Figure 4. The MTs of AS, BA and
AQ are respectively 2.82, 3.29, and 5.65 min. The small
peak eluted at 3.13 min. is an impurity of AQ, which is
evidenced when AQH is present at high concentration.
Evaluation of method performances
The method was validated according the guidelines of
the international conference of harmonisation [14].
Selectivity
The non-interference of ingredients present in the tab-
let formulations (Table 2) on the analyte peaks was
assessed (Figure 5a) by injecting a blank solution of
excipients. No interference was noted. As it was also
considered that the method could be potentially applic-
able to detect counterfeit anti-malarial formulations
[15], the selectivity was also tested (Figure 5a) towards
common anti-malarials: artemether (AM), lumefantrine
(LUM), quinine (QUI), pyrimethamine (PYR), and sul-
phadoxine (SDX).SDX, AM, LUM, PYR are separated
from AS and AQ. QUI which is eluted at a MT very
close to AQ could be differenciated from AQ by its UV
spectrum (Figure 5b). Lumefantrine, which is a very
hydrophobic compound, was not soluble in the dissolving
solvent.
Linearity of the response function
The linearity of the response function (corrected peak
areas, CPA analyte/IS) vs analyte concentration was
assessed on standard solutions over the range 1–3 g L-1
for AS and 35–105 mg L-1 for AQH at 5 concentration
levels corresponding to 50, 75, 100, 125, and 150% of the
target concentration of AS (2 g L-1) and AQH (70 mg L-1).
Regression equations calculated using the least-squares
method were:
CPA AS=ISð Þ ¼ 0:000174 0:000013ð ÞASmg L1
 0:0216 0:0260ð Þ; r2 ¼ 0:999
CPA AQH=ISð Þ¼ 0:0156 0:0009ð ÞAQHmg L1
þ 0:059 0:063ð Þ; r2 ¼ 0:996
with the confidence intervals calculated at α= 0.05, ana-
lysis of variance shows that the relationship is linear and
that the regression line passes through the origin.
System precision
The precision of the system was assessed by injecting seven
times successively a standard solution at the target concen-
tration and a test solution. The RSD values were typically
better than 0.2% for RMTs (MTs relative to IS) and in the
Figure 4 Determination of AS, 2 g L−1 (a) and AQH, 70 mg L−1 (b). Electropherograms of a standard solution (lower trace) and CoarsucamW
test solution (upper trace). Conditions as in Figure 3.
Table 2 Excipients of the different pharmaceutical
formulations analysed
Excipients CoarsucamW ASAQ DenkW
Sodium croscarmellose x x
Povidone K30 x
Magnesium stearate x x
Colloidal anhydrous silica x x
Calcium carbonate x
Maize starch x
Microcrystalline cellulose x x
Talc x
Calcium hydrogen phosphate dihydrate x
Lactose monohydrate x
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range 1 – 3% for RCPAs (CPAs relative to IS). Similar
RMTs (0.85 for AS and 1.70 for AQ) were obtained on a
same day, on different days, on different capillaries and dif-
ferent instruments. RMTs can be used together with UV
spectra to confirm the identity of the drugs.
Accuracy: Recovery studies
The accuracy of the method was assessed by perform-
ing recovery experiments. Three series of independent
determinations were carried out, each time at three
concentration levels of AS and AQH. For each series,
analytical placebos spiked with amounts of AS and
AQH corresponding to 80, 100 and 120% of the target
concentration were prepared. Recoveries of AS and
AQH were calculated against a standard solution at the
target concentration prepared in duplicate (Table 3).
AS and AQH mean recoveries were at 101-102% and
98-99% respectively.
Limit of quantification (LOQ)
The LOQ (signal-to-noise ratio of 10) is about 330 mg L-1
for AS and 3.5 mg L-1 for AQH. These limits correspond to
LOQs of 16.5 mg and 0.2 mg of AS and AQH respectively
in a tablet of 700 mg.
Application to commercial tablet formulations
Different fixed-dose combination tablets (CoarsucamW and
ASAQ DenkW) were analysed for AS and AQH content
using the proposed CE method. Duplicate independent
determinations were carried out except for CoarsucamW
50 mg AS – 176.32 mg AQH for which seven replicate in-
dependent determinations were carried out to test the re-
peatability of the entire analytical procedure (Table 4). The
repeatability expressed as the relative standard deviation
was, 2.04% for AS and 3.00% for AQ.
Conclusion
MEKC can be used for the determination of AS and AQH
in fixed-dose combination tablet formulations. Satisfactory
results were obtained for method validation according to
the ICH guidelines with respect to selectivity, linearity of
the calibration line, accuracy and precision. The method
presents an interesting alternative to liquid chromatography
for drug quality control and detection of counterfeit or sub-
standard medicines in developing countries. It should be
Figure 5 (a) Selectivity towards formulation excipients and common anti-malarials; (b) UV spectra of anti-malarials recorded with the
diode array detector. Experimental conditions as in Figure 3.
















1 15.84 16.23 102
2 80 15.99 16.12 101 101 ± 0.8
3 16.16 16.35 101
1 19.85 20.21 102
2 100 19.97 20.61 103 102 ± 0.7
3 20.06 20.48 102
1 23.57 23.46 100
2 120 24.00 24.54 102 101 ± 1.4
3 24.17 24.44 101
AQH
1 55.26 54.74 99
2 80 55.65 55.03 99 99 ± 0.3
3 56.81 56.47 99
1 69.3 68.49 99
2 100 70.31 69.16 98 98 ± 0.9
3 70.87 68.84 97
1 83.2 82.69 99
2 120 85.05 83.06 98 99 ± 1.1
3 93.92 93.47 100
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emphasized that, thanks to a European project, low-cost ca-
pillary electrophoresis machines are now installed in Mali,
Cambodia and will be soon installed in Congo and Senegal
for this aim [16]. The main advantages of CE over liquid
chromatography are the low running cost: low price of the
capillary (about 4 dollars) which has a long lifetime (more
than 300 injections) and low consumption of separation
electrolyte (in the order of 10 mL per day) which makes the
price of a test more cost efficient.
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Table 4 Assay of commercial tablet formulations




CoarsucamW; 25 mg AS – 88.16 mg AQH (67.5 mg AQ base) 101.6 99.6
CoarsucamW; 50 mg AS – 176.32 mg AQH (135 mg AQ base) 98.1 100.2
CoarsucamW; 100 mg AS – 352.64 mg AQH (270 mg AQ base) 97.0 98.1
ASAQ DenkW; 100 mg AS – 352.64 mg AQH (270 mg AQ base) 98.0 99.5
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